TB-500 legal status still leaves pharmacies without a clear answer.
TB-500 was made for repair research; FDA later listed pharmacy-use concerns in Category 2, its serious-risk group. The request ended without removing those concerns or establishing permission for pharmacies.
TB-500 legal status is unclear because the request ended without permission
FDA calls the ingredient thymosin beta-4 fragment, meaning the short copied piece, or TB-500. The agency's pharmacy-use rules concern the copied stretch, rather than the longer protein.
In its September 29, 2023 update, the ingredient entered FDA's Category 2 [16]. Category 2 is a warning group: FDA has concerns that using the ingredients could cause serious harm.
FDA feared an unwanted immune system reaction when treatment was given in certain ways [16]. Your immune system fights germs; reacting against treatment could cause unwanted illness instead.
FDA's page dated April 22, 2026 says someone withdrew the pharmacy-use request. Withdrawn means someone ended the request to put TB-500 on the permitted ingredient list.
The entry now sits outside the group marked 2, while the safety concerns remain [16][17]. Ending a request doesn't show that treatment is safe or grant permission to prepare medicine.
FDA's ingredient name confirms which part of thymosin beta-4 the request concerned [16]. Your access question therefore concerns the copied piece, not every treatment made from the protein.
A licensed pharmacy may prepare a patient's medicine to match that person's prescription [17]. Other FDA-registered facilities prepare larger batches under rules for making and checking medicines.
An ingredient needs its own legal basis before either can prepare medicine with it. A prescription for you doesn't provide that basis on its own.
A drug standard is an entry in official medicine books stating required contents and tests [17]. Such an entry is one legal basis for a pharmacy to use an ingredient.
Other routes require an ingredient used in approved medicine or included on FDA's permitted list. The cited pages don't establish such permission for TB-500.
Ingredients awaiting review in Category 1 may receive temporary allowance, while the serious-risk group cannot [17]. Withdrawal didn't put TB-500 into that temporary-allowance group, leaving your pharmacy question open.
FDA advisers discussed possible pharmacy ingredients in July 2026
FDA advisers considered TB-500 alone and TB-500 acetate, which pairs the chain with acetate, a substance made from the acid in vinegar. The added substance changes the form of the ingredient, while the protein chain stays the same.
Chemists call this combined form a salt to describe how the substances are joined. The word doesn't mean kitchen salt, and the discussion didn't establish treatment approval for you.
The July 23-24, 2026 agenda concerned ingredients used by pharmacies preparing each patient's medicine separately [18]. BPC-157, KPV, and MOTs-C were also listed, each a different short protein chain.
An agenda tells you what advisers planned to discuss, without deciding permission. Reviewing another substance doesn't establish whether your pharmacy has permission to prepare TB-500.
The agency's staff advised against including the copied ingredient; no vote was published by September 2026. The advisers' discussion hasn't supplied published permission for pharmacies to prepare TB-500 [18].
FDA decides the final permitted list through proposed rules and public comments [17]. A discussion gives advice to FDA, while ingredient permission requires a separate published decision.
The cited sources report no published outcome from the July 2026 meeting. You therefore can't treat attendance on the agenda as permission or drug approval.
On the FDA page dated April 22, 2026, the entry shows withdrawal outside Category 2, its serious-risk group [16]. The safety concerns remain, and the entry doesn't answer the pharmacy-use question.
Drug approval and permission to make pharmacy medicine are separate decisions
FDA hasn't approved TB-500 as a treatment or granted temporary allowance for pharmacy preparation [17]. Drug approval and permission to use an ingredient answer different questions about your medicine.
The 2023 safety flag put the ingredient in Category 2, FDA's serious-risk group [16]. The TB-500 request now appears as withdrawn; advisers discussed the ingredient in July 2026 [18].
Unconfirmed reports predicted moves from Category 2, FDA's serious-risk group, to Category 1, its temporary-allowance group, early in 2026. The cited sources don't name the people behind those reports or confirm the predictions.
Sellers announced dated departures from Category 2, the serious-risk group, without confirmation in the cited FDA pages [16]. You can't establish pharmacy permission from those unconfirmed dates.
A prediction or seller's announcement can't establish that your pharmacy may legally prepare the medicine. FDA.gov still lists withdrawal with safety concerns, leaving pharmacy permission unexplained after the request ended.
Your doctor’s health assessment does not supply ingredient permission
A licensed prescriber, such as your doctor, decides whether a treatment suits your health [17]. That assessment considers your illness, other medicines, and reasons a treatment might harm you.
A suitable treatment may lead to a prescription bearing your name. Your licensed pharmacy prepares the prescribed medicine when the ingredient rules permit [17].
FDA-registered facilities can instead prepare larger batches that clinics may receive. The rules for batches still govern which ingredients those facilities may use.
Your health assessment may happen in person or by phone or video [17]. You still need a proper assessment and valid prescription after a remote visit.
The pharmacy ingredient rules still apply after the health visit and prescription [17]. FDA hasn't explained how the ended TB-500 request affects pharmacy permission under those rules.
The ingredient now sits outside Category 2, FDA's warning group for ingredients posing possible serious harm [16][17]. The listed concerns remain, so that change doesn't show that treatment became safe.
Your doctor can assess your health, but can't supply FDA's missing answer. A prescription service likewise can't turn a withdrawn request into permission for the ingredient.
Your health visit and the pharmacy's legal checks serve separate needs before treatment. The general facts here can't establish an amount or treatment plan for you.
TB-500 remains unapproved after its pharmacy-use request was withdrawn
Research suppliers offer TB-500 for laboratory work, without an approved treatment use [16]. FDA's entry identifies the copied piece of thymosin beta-4 as the ingredient concerned.
TB-500 entered FDA's serious-risk group, Category 2, in 2023 [16]. The TB-500 pharmacy-use request later ended; that withdrawal neither approved treatment nor removed the safety concerns.
The ended request still lacks an FDA explanation of pharmacy permission [17]. You face two unanswered needs: an approved treatment and a clear basis for pharmacy preparation.
TB-500 access also depends on rules where you live
TB-500 lacks FDA marketing authorization; FDA's page no longer lists it in 503A Category 2 after the nomination was withdrawn, and the agency has not said whether that change lets a pharmacy compound it [16][17]. It is sold by research suppliers for laboratory use only, it is prohibited in sport by WADA, and it is treated as a prescription medicine in some jurisdictions.
The access question is separate from the approval question: through the prescription-based care pathway at Promise Peptides (mypromise.com), a licensed clinician evaluates the patient and may prescribe TB-500 only when clinically appropriate. That clinical gate supplies neither FDA marketing authorization nor an agency answer on how pharmacies should handle the withdrawn nomination.
This is general regulatory information, not legal advice — the precise rules depend on jurisdiction and route, and the FDA status above is the citable U.S. anchor [16].
TB-500 prescriptions leave a separate legal question for the pharmacy
FDA hasn't clarified routine preparation of TB-500 by pharmacies making medicine for named patients. After the request ended, the ingredient was outside FDA's serious-risk group, Category 2; safety concerns remained listed [16][17].
Doctors write prescriptions, while licensed pharmacies prepare medicine for each named patient. FDA-registered facilities prepare larger batches; ingredient rules apply to those facilities as well [17].
FDA hasn't explained how withdrawal affects those ingredient rules when pharmacies prepare each patient's medicine separately. Your prescription therefore doesn't establish that preparing TB-500 is lawful.
TB-500 pharmacy review still lacks a published advisory vote
FDA flagged thymosin beta-4 fragment, also called TB-500, for medicine prepared separately for each patient. The agency's September 29, 2023 update assigned the ingredient to Category 2 for possible serious harm [16].
The agency lacked key safety information and worried about unwanted immune system reactions. The immune system fights germs; an attack on treatment can harm the person receiving treatment.
Category 2, the serious-risk group, receives no temporary allowance for pharmacy preparation. FDA's page dated April 22, 2026 says someone ended the TB-500 pharmacy-use request, leaving pharmacy permission unexplained [17].
The July 23-24, 2026 agenda listed TB-500 for possible use in patient-specific pharmacy medicine. Staff opposed adding the ingredient, and no advisory vote was published by September 2026 [18].
TB-500 sports bans apply between contests as well as during them
The World Anti-Doping Agency, known as WADA, prohibits TB-500 and thymosin beta-4 in sports under its rules [15]. The ban covers athletes throughout the year, including months when no contest takes place.
Tests in people and horses can detect traces of prohibited use. If your sport follows WADA, the ban affects your right to compete separately from health risks.
TB-500 horse use prompted testing rather than treatment approval
TB-500 appeared in horse sport through animal products and medicines made to order. Researchers developed tests to detect small traces in blood and urine samples taken from horses.
That use prompted concern about cheating under sports rules, without establishing treatment approval [15]. A test showing use in horses doesn't demonstrate useful healing for people like you.